HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hillhouse Capital Related

513.048

-0.450-0.09%

Number of Gainers:28

Number of Losers:19

Number of Flat:8

PE:- -

High:516.134

Open:513.498

Low:507.279

Close:513.498

Loading ...

MicroPort Scientific Corporation Conducted Annual General Meeting

BRIEF-Anhui Conch Cement Announces Election Of Yang Jun As Chairman

Anhui Conch Cement - Elected Yang Jun as Chairman

THOMSON REUTERS

Meituan's Strong Competitive Efforts to Dampen Margins, S&P Says

MT Newswires Live

Top Win Unveils Strategic Investments And Ticker Change To Drive Digital Assets Innovation In Asia

Modern Dental Group Ltd. Conducted Annual General Meeting

Hansoh Pharmaceutical Group Announces NMPA Approval for Clinical Trials of Innovative HS-10510 Tablets

Hansoh Pharmaceutical - Clinical Trial Approval for Hs-10510 Tablets Issued by Nmpa

THOMSON REUTERS

Hansoh Pharmaceutical - Clinical Trial Approval for Hs-20118 Tablets Issued by Nmpa

THOMSON REUTERS

Genor Biopharma Secures NMPA Approval for Lerociclib to Treat Advanced Breast Cancer

Genor Biopharma - Nmpa Granted New Drug Application Approval for Lerociclib (Gb491)

THOMSON REUTERS

Innovent Biologics Initiates Phase 3 Trial of Picankibart for Psoriasis Patients with Prior Inadequate Anti-IL-17 Response

Innovent Announces a Phase 3 Study of Picankibart (Anti-Il-23P19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients With Prior Inadequate Response to Anti-Il-17 Antibodies

THOMSON REUTERS

Luye Pharma Group Ltd. Conducted Annual General Meeting

Frontage Holdings Corporation Conducted Annual General Meeting

HBM Holdings Ltd. Files Next Day Disclosure to HKEX Announcing Repurchase of 500,000 Shares at HKD 4,166,000

Zylox-Tonbridge Files Next Day Disclosure with HKEX: Announces 80,000 Shares Repurchased at HKD 1,456,480

Youzan Technology Ltd. Announces Buyback of 700,000 Shares for HKD 60,200

LifeTech Scientific Corporation Conducted Annual General Meeting

Jinke Smart Services Group Co. Ltd. Discloses Internal Dealing Involving CICC Financial Trading Limited's Derivative Contract

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1583/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":513.04846,"timestamp":1749197315346,"preClose":513.49805,"halted":0,"volume":787771556,"delay":0,"changeRate":-0.000876,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-0.449585,"latestTime":"06-06 16:00:00","open":513.49805,"high":516.1344,"low":507.27917,"amount":15627538503,"amplitude":0.017245,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749432600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749173400000,1749182400000],[1749186000000,1749196800000]],"pbRate":2.358598,"peRate":21.998152,"turnoverRate":0.005389,"increases":30,"decrements":20,"flats":4,"marketCap":2901322639680,"floatMarketCap":2286727975232},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":516.1344,"amplitude":0.017245,"preClose":513.49805,"low":507.27917,"pbRate":"2.358598","latestPrice":513.04846,"volume":787771556,"delay":0,"open":513.49805,"prevYearClose":446.93042,"prevWeekClose":496.286,"prevMonthClose":496.286,"prevQuarterClose":505.776,"fiveDayClose":496.286,"twentyDayClose":480.539,"sixtyDayClose":530.16,"secType":"PLATE","market":"HK","turnoverRate":0.005389,"peRate":21.998152,"marketCap":2901322639680,"floatMarketCap":2286727975232,"timestamp":1749197315346,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":28,"down":19,"flat":8},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2539244850","title":"MicroPort Scientific Corporation Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2539244850","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539244850?lang=en_us&edition=fundamental","pubTime":"2025-05-30 16:56","pubTimestamp":1748595408,"startTime":"0","endTime":"0","summary":"MicroPort Scientific Corporation held its Annual General Meeting on 30 May 2025. During the meeting, shareholders voted on several proposals. The proposal to receive the audited consolidated financial statements of the company and the reports of the directors and auditor for the year ended 31 December 2024 was approved. Additionally, the proposal to re-elect Dr. Zhaohua Chang as an executive director of the company was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MicroPort Scientific Corporation published the original content used to generate this news brief on May 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL20G0Qg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1583","00853","BK1585","BK1100"],"gpt_icon":0},{"id":"2539626312","title":"BRIEF-Anhui Conch Cement Announces Election Of Yang Jun As Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2539626312","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539626312?lang=en_us&edition=fundamental","pubTime":"2025-05-29 21:15","pubTimestamp":1748524521,"startTime":"0","endTime":"0","summary":"BRIEF-Anhui Conch Cement Announces Election Of Yang Jun As ChairmanMay 29 (Reuters) - Anhui Conch Cement Co Ltd 600585.SS:ELECTED YANG JUN AS CHAIRMANELECTED ZHU SHENGLI AS DEPUTY CHAIRMANFurther company coverage: 600585.SS ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nFWN3S10IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1507","600585","BK0015","BK0235","BK1505","BK0028","BK0196","BK1583","BK0183","BK1563","BK1594","BK0044","LU1328615791.USD","BK1135","BK0188","00914","BK0012","BK0187"],"gpt_icon":0},{"id":"2539263953","title":"Anhui Conch Cement -  Elected Yang Jun as Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2539263953","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539263953?lang=en_us&edition=fundamental","pubTime":"2025-05-29 21:14","pubTimestamp":1748524453,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nFWN3S10IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1507","600585","BK0015","BK0235","BK1505","BK0028","BK0196","BK1583","BK0183","BK1563","BK1594","BK0044","LU1328615791.USD","BK1135","BK0188","00914","BK0012","BK0187"],"gpt_icon":0},{"id":"2539250486","title":"Meituan's Strong Competitive Efforts to Dampen Margins, S&P Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2539250486","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539250486?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:21","pubTimestamp":1748521303,"startTime":"0","endTime":"0","summary":"Meituan's  spending boost to counter competitors will weaken its operating margin in 2025, S&P Global Ratings said in a Thursday release.The China-based online delivery giant has offered more incentives to both users and merchants amid JD.com's  entry into the market.This aggressive stance will curb the company's EBITDA expansion even with solid first-quarter earnings, S&P said.The rating agency lowered its forecast for the company's EBITDA margin by 100 to 200 basis points over the next two years to between 12% and 13%.Although government efforts to support merchants will have a limited direct impact on the company, it will also contend with competitive pressures, new business losses, and the implementation of rider benefits, the rating agency said.Despite these headwinds, S&P expects the company's credit profile to improve, given its financial discipline and a decent cash buffer.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1188198961.HKD","SG9999001226.SGD","LU0370786039.SGD","LU0499858602.USD","LU2226246903.HKD","LU1328277881.USD","89618","LU0543330483.HKD","LU1960683339.HKD","LU0828238088.HKD","LU1868837565.USD","LU0856984785.SGD","LU0819121731.USD","03690","LU1282651048.USD","LU0878005551.USD","LU1152091168.USD","LU1282649067.USD","LU1880383366.USD","LU0541501648.USD","MPNGY","LU2097828557.USD","LU0871576103.HKD","LU0456827905.SGD","LU0359201885.HKD","LU1282651121.HKD","BK1583","LU0577902454.USD","LU1044874839.SGD","LU0605514214.HKD","METmain","LU0029875118.USD","LU0828237940.HKD","LU0828237510.HKD","LU0672654166.SGD","LU0348805143.USD","IE00BF5LJ272.USD","HMTD.SI","IE00B5MMRT66.SGD","LU0359202008.SGD","LU0588546209.SGD","LU0501845795.SGD","LU0196878994.USD","LU0149721374.USD","LU1807302812.USD","LU1366334578.USD","LU0577902298.EUR","BK1604"],"gpt_icon":1},{"id":"2539250901","title":"Top Win Unveils Strategic Investments And Ticker Change To Drive Digital Assets Innovation In Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2539250901","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539250901?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:20","pubTimestamp":1748521211,"startTime":"0","endTime":"0","summary":"May 29 (Reuters) - :*TOP WIN UNVEILS STRATEGIC INVESTMENTS AND TICKER CHANGE TO DRIVE DIGITAL ASSETS INNOVATION IN ASIA*TOP WIN INTERNATIONAL LTD: APPOINTED JASON FANG AS CHAIRMAN OF BOARD*TOP WIN INT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nRSD4WS1pb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","03692","BK1589","BK1191"],"gpt_icon":0},{"id":"2539509422","title":"Modern Dental Group Ltd. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2539509422","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539509422?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:17","pubTimestamp":1748521068,"startTime":"0","endTime":"0","summary":"Modern Dental Group Ltd. held its Annual General Meeting on May 29, 2025. The meeting saw the approval of several proposals. The audited consolidated financial statements and the reports of the directors and auditors for the year ended December 31, 2024, were received and considered. A final dividend out of the share premium account was declared. Ms. Chan Yik Yu was re-elected as an executive director, and Mr. Chan Chi Yuen was also re-elected as an executive director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modern Dental Group Ltd. published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL2T9XPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1100","BK1583","03600"],"gpt_icon":0},{"id":"2539251024","title":"Hansoh Pharmaceutical Group Announces NMPA Approval for Clinical Trials of Innovative HS-10510 Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2539251024","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539251024?lang=en_us&edition=fundamental","pubTime":"2025-05-29 18:46","pubTimestamp":1748515588,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL4p4zJp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","03692","BK1589","BK1191"],"gpt_icon":0},{"id":"2539591292","title":"Hansoh Pharmaceutical -  Clinical Trial Approval for Hs-10510 Tablets Issued by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2539591292","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539591292?lang=en_us&edition=fundamental","pubTime":"2025-05-29 18:15","pubTimestamp":1748513749,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nFWN3S110B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","03692","BK1589","BK1583"],"gpt_icon":0},{"id":"2539821259","title":"Hansoh Pharmaceutical - Clinical Trial Approval for Hs-20118 Tablets Issued by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2539821259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539821259?lang=en_us&edition=fundamental","pubTime":"2025-05-29 18:06","pubTimestamp":1748513210,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nFWN3S10SC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","03692","BK1583","BK1589"],"gpt_icon":0},{"id":"2539723716","title":"Genor Biopharma Secures NMPA Approval for Lerociclib to Treat Advanced Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2539723716","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539723716?lang=en_us&edition=fundamental","pubTime":"2025-05-29 16:59","pubTimestamp":1748509188,"startTime":"0","endTime":"0","summary":"Genor Biopharma Holdings Ltd. has announced that the China National Medical Products Administration  has granted approval for the new drug application of Lerociclib . This novel, highly potent, selective oral bioavailable cyclin-dependent kinases 4 and 6 inhibitor  has been co-developed by Genor Biopharma and G1 Therapeutics Inc. It is designed for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative  locally advanced or metastatic breast cancer. Lerociclib will be used in combination with an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant in patients whose disease has progressed following endocrine therapy. This approval represents a significant milestone for Genor Biopharma and showcases the successful collaboration with G1 Therapeutics Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL8XC61z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06998","BK1583","BK1161","BK1574"],"gpt_icon":0},{"id":"2539376982","title":"Genor Biopharma - Nmpa Granted New Drug Application Approval for Lerociclib (Gb491)","url":"https://stock-news.laohu8.com/highlight/detail?id=2539376982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539376982?lang=en_us&edition=fundamental","pubTime":"2025-05-29 16:48","pubTimestamp":1748508491,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nFWN3S10H0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","06998","BK1583","BK1161"],"gpt_icon":0},{"id":"2539868342","title":"Innovent Biologics Initiates Phase 3 Trial of Picankibart for Psoriasis Patients with Prior Inadequate Anti-IL-17 Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2539868342","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539868342?lang=en_us&edition=fundamental","pubTime":"2025-05-29 09:33","pubTimestamp":1748482418,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. Announces Phase 3 Clinical Study of Picankibart for Psoriasis Innovent Biologics, Inc. has announced the initiation of a Phase 3 clinical study to evaluate picankibart, an anti-IL-23p19 antibody, in treating psoriasis patients who have had an inadequate response to anti-IL-17 antibodies. The study recently completed the first participant dosing and is the first of its kind to explore biologics switching in this patient population. The trial will compare the efficacy of picankibart against IL-17 inhibitors. Previous Phase 2 data indicated that picankibart achieved significant skin lesion clearance in 64.6% of patients after 16 weeks. The study aims to provide clinical evidence supporting picankibart's use as an alternative treatment option for challenging cases of psoriasis. Innovent's new drug application for picankibart for moderate-to-severe plaque psoriasis is currently under review by the NMPA.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL5yWrZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","01801","LU2488822045.USD","LU1969619763.USD","01911","BK1161","LU2328871848.SGD","BK1589","BK1147"],"gpt_icon":0},{"id":"2539891286","title":"Innovent Announces a Phase 3 Study of Picankibart (Anti-Il-23P19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients With Prior Inadequate Response to Anti-Il-17 Antibodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2539891286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539891286?lang=en_us&edition=fundamental","pubTime":"2025-05-29 09:33","pubTimestamp":1748482401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA4VKCRX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1583","LU2488822045.USD","LU1969619763.USD","BK1589","LU2328871848.SGD","01801"],"gpt_icon":0},{"id":"2538474300","title":"Luye Pharma Group Ltd. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2538474300","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538474300?lang=en_us&edition=fundamental","pubTime":"2025-05-28 22:03","pubTimestamp":1748441006,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd. held its Annual General Meeting on 28 May 2025. During the meeting, several proposals were put forward and approved. Mr. HUANG Liming was re-elected as a non-executive Director, and Professor LO Yuk Lam was re-elected as an independent non-executive Director. Ms. XIA Lian was also re-elected as an independent non-executive Director. Additionally, Ernst & Young was re-appointed as the Auditor to hold office until the conclusion of the next annual general meeting of the Company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL9WtcnG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","02186","BK1583","BK1191"],"gpt_icon":0},{"id":"2538479517","title":"Frontage Holdings Corporation Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2538479517","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538479517?lang=en_us&edition=fundamental","pubTime":"2025-05-28 21:04","pubTimestamp":1748437445,"startTime":"0","endTime":"0","summary":"Frontage Holdings Corporation held its Annual General Meeting on May 28, 2025. All resolutions proposed at the meeting were approved. Dr. Zhihe Li ceased to be a Non-executive Director, while Dr. Wentao Zhang and Dr. Zhongping Lin were appointed as Executive Directors. The Board expressed gratitude to Dr. Zhihe Li for contributions during the tenure and welcomed the new members.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Frontage Holdings Corporation published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL8Vq3cM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0077","BK0028","LU1820825898.SGD","BK1576","BK1583","01521","BK0174","300347","BK0216","BK1141","LU1146622755.USD"],"gpt_icon":0},{"id":"2538475138","title":"HBM Holdings Ltd. Files Next Day Disclosure to HKEX Announcing Repurchase of 500,000 Shares at HKD 4,166,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2538475138","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538475138?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:16","pubTimestamp":1748434581,"startTime":"0","endTime":"0","summary":"HBM Holdings Ltd. has filed a next day disclosure return with the Hong Kong Stock Exchange, reporting the repurchase of 500,000 shares. The shares were repurchased at a price of HKD 8.332 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL2RKhK7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02142","BK1583","BK1161"],"gpt_icon":0},{"id":"2538473046","title":"Zylox-Tonbridge Files Next Day Disclosure with HKEX: Announces 80,000 Shares Repurchased at HKD 1,456,480","url":"https://stock-news.laohu8.com/highlight/detail?id=2538473046","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538473046?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:01","pubTimestamp":1748433695,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge Medical Technology Co., Ltd. has filed a next day disclosure return with the Hong Kong Stock Exchange, detailing the repurchase of 80,000 shares to be held as treasury shares. The aggregate price paid for the repurchase was HKD 1,456,480.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zylox-Tonbridge Medical Technology Co .Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL44Km65:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02190","BK1100","BK1574","BK1587","BK1583"],"gpt_icon":0},{"id":"2538473970","title":"Youzan Technology Ltd. Announces Buyback of 700,000 Shares for HKD 60,200","url":"https://stock-news.laohu8.com/highlight/detail?id=2538473970","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538473970?lang=en_us&edition=fundamental","pubTime":"2025-05-28 19:50","pubTimestamp":1748433016,"startTime":"0","endTime":"0","summary":"Youzan Technology Ltd. has completed a share buyback transaction, as disclosed in their Next Day Disclosure Return submitted on 28 May 2025. The transaction was conducted on the Stock Exchange of Hong Kong Limited. Further details regarding the total number of shares or the specific price per share were not disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Youzan Technology Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL50Gq38:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1516","BK1583","BK1109","BK1518","BK1590","08083"],"gpt_icon":0},{"id":"2538420058","title":"LifeTech Scientific Corporation Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2538420058","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538420058?lang=en_us&edition=fundamental","pubTime":"2025-05-28 19:11","pubTimestamp":1748430687,"startTime":"0","endTime":"0","summary":"LifeTech Scientific Corporation held its annual general meeting on 28 May 2025. During the meeting, several proposals were considered and approved. The audited consolidated financial statements for the year ended 31 December 2024, along with the reports of the directors and the independent auditor, were adopted. Additionally, Mr. XIE Yuehui and Mr. LIU Jianxiong were re-elected as executive directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeTech Scientific Corporation published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL46NYy0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1600","01302","BK1100"],"gpt_icon":0},{"id":"2538422309","title":"Jinke Smart Services Group Co. Ltd. Discloses Internal Dealing Involving CICC Financial Trading Limited's Derivative Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2538422309","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538422309?lang=en_us&edition=fundamental","pubTime":"2025-05-28 18:05","pubTimestamp":1748426700,"startTime":"0","endTime":"0","summary":"Jinke Smart Services Group Co. Ltd. Discloses Internal Dealing Involving CICC Financial Trading Limited's Derivative Contract. Jinke Smart Services Group Co. Ltd. announced a disclosure of internal dealings under Rule 22 of the Hong Kong Code on Takeovers and Mergers. On 27 May 2025, CICC Financial Trading Limited, an exempt principal trader connected with the Offeror, entered into a derivative contract involving 39,500 reference securities, set to mature on 28 May 2026. CICC Financial Trading Limited is owned by China International Capital Corporation Limited.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jinke Smart Services Group Co. Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL1DycrN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1258","09666","BK1542","BK1229","BK0188","BK0028","BK0276","BK0174","BK1583","601995","BK0273","000656"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":94,"code":"91000000","status":"200"}]}}